Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박소영 | - |
dc.contributor.author | 공현식 | - |
dc.contributor.author | 김경민 | - |
dc.contributor.author | 김담 | - |
dc.contributor.author | 김하영 | - |
dc.contributor.author | 전찬홍 | - |
dc.contributor.author | 주지현 | - |
dc.contributor.author | 이신석 | - |
dc.contributor.author | 박동아 | - |
dc.contributor.author | 성윤경 | - |
dc.contributor.author | 김상완 | - |
dc.date.accessioned | 2021-07-30T04:56:22Z | - |
dc.date.available | 2021-07-30T04:56:22Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2018-11 | - |
dc.identifier.issn | 2287-6375 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/2290 | - |
dc.description.abstract | Background: To develop guidelines and recommendations to prevent and treat glucocorticoid (GC)-induced osteoporosis (GIOP) in Korea. Methods: The Korean Society for Bone and Mineral Research and the Korean College of Rheumatology have developed this guideline based on Guidance for the Development of Clinical Practice Guidelines ver. 1.0 established by the National Evidence-Based Healthcare Collaborating Agency. This guideline was developed by adapting previously published guidelines, and a systematic review and quality assessment were performed. Results: This guideline applies to adults aged ≥19 years who are using or plan to use GCs. It does not include children and adolescents. An initial assessment of fracture risk should be performed within 6 months of initial GC use. Fracture risk should be estimated using the fracture-risk assessment tool (FRAX) after adjustments for GC dose, history of osteoporotic fractures, and bone mineral density (BMD) results. All patients administered with prednisolone or an equivalent medication at a dose ≥2.5 mg/day for ≥3 months are recommended to use adequate calcium and vitamin D during treatment. Patients showing a moderate-to-high fracture risk should be treated with additional medication for osteoporosis. All patients continuing GC therapy should undergo annual BMD testing, vertebral X-ray, and fracture risk assessment using FRAX. When treatment failure is suspected, switching to another drug should be considered. Conclusions: This guideline is intended to guide clinicians in the prevention and treatment of GIOP. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한골대사학회 | - |
dc.title | Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 성윤경 | - |
dc.identifier.doi | 10.11005/jbm.2018.25.4.195 | - |
dc.identifier.bibliographicCitation | 대한골대사학회지, v.25, no.4, pp.195 - 211 | - |
dc.relation.isPartOf | 대한골대사학회지 | - |
dc.citation.title | 대한골대사학회지 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 195 | - |
dc.citation.endPage | 211 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002411621 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Bisphosphonate | - |
dc.subject.keywordAuthor | Denosumab | - |
dc.subject.keywordAuthor | Glucocorticoids | - |
dc.subject.keywordAuthor | Osteporosis | - |
dc.subject.keywordAuthor | Teriparatide | - |
dc.identifier.url | https://synapse.koreamed.org/articles/1109067 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.